Skip to Content

Jogging Hearts Back to Health

Replacement cells from an unlikely source-leg muscle-could help heart attack victims live longer.
June 1, 2004

Each year millions of people around the world survive heart attacks but then must live with scarred, weakened hearts that frequently enlarge to compensate for a diminished ability to pump blood. Ultimately, this condition can lead to heart failure and death. Researchers are finding some early signs that replacement cells from an unlikely source-leg muscle-could bulk up diseased hearts, helping to prolong life in heart attack victims.

Genzyme of Cambridge, MA, is now conducting tests of the treatment strategy in France and several other European countries with 300 heart attack patients. Researchers take muscle cells from a patient, cultivate a select group of those cells in petri dishes for two to three weeks, and then inject them directly into the heart’s scar tissue. Preliminary research suggests these replacement cells strengthen the damaged wall of the heart, preventing bulging, says Ralph Kelly, vice president of clinical research for Genzyme.

GenVec of Gaithersburg, MD, and Bioheart of Weston, FL, have begun human tests of a similar technology in the United States. If the trials go well, in five to ten years, leg-muscle-cell injection could become an approved therapy, says John Fakunding, program director for heart research at the National Heart, Lung, and Blood Institute in Bethesda, MD. The treatment could potentially prolong life, Fakunding says. “The transplantation [of muscle cells] into the heart does appear to have a functional benefit,” he says, “in that it may make the heart work better.”

Most experts, however, suggest that the use of leg muscle is a short-term patch. For one thing, leg muscle cells don’t beat, as cardiac cells do. And some researchers suspect that implantation can lead to arrhythmias, or irregular heart beating, in some patients. But leg muscle cells may well play a role “until better reparative methods, using other cells and transplantation methods, are developed,” Fakunding says. Despite the caveats, that’s hopeful news for people at risk for heart failure.

Keep Reading

Most Popular

This startup wants to copy you into an embryo for organ harvesting

With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.

VR is as good as psychedelics at helping people reach transcendence

On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.